title: [Prognostic and predictive factors in multifocal breast carcinoma].
abstract: OBJECTIVE
  Multicentricity is not listed as a major prognostic parameter in invasive breast carcinoma, and is not by itself an indication of systemic adjuvant treatment. Furthermore, evaluating the size of these tumors is discussed. The aims of this study are to evaluate prognostic value of multicentricity, and to compare different way for measuring multicentric breast carcinomas.
  
  
  METHODS
  Between 2001 and 2008, 1458 patients having breast invasive carcinoma were included in Tenon Hospital, Paris, France; 16% had a multicentric cancer. We have compared impact of multicentricity on lymph node (LN) involvement, and compared 3 ways for measuring these cancers.
  
  
  RESULTS
  LN involvement was significantly associated with multicentricity. We found an over-risk of 20% for LN involvement in patients having multicentric cancer, whatever the size of the tumors. Considering the diameter of the largest focus is the best way for measuring these cancers.
  
  
  CONCLUSIONS
  We did not find a subgroup of patients at low risk of LN involvement when having a multicentric breast cancers. These results lead us to extend indications of adjuvant chemotherapies in all multicentric breast cancer. These results should be validated by randomized prospective studies.
authors.affiliation: Service de gynécologie-obstétrique et médecine de la reproduction, hôpital Tenon, AP-HP, université Pierre-et-Marie-Curie Paris-6, 4 rue de la Chine, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Moutafoff
authors.forename: C
authors.initials: C
authors.lastname: Coutant
authors.forename: C
authors.initials: C
authors.lastname: Bézu
authors.forename: M
authors.initials: M
authors.lastname: Antoine
authors.forename: G
authors.initials: G
authors.lastname: Werkoff
authors.forename: A
authors.initials: A
authors.lastname: Benbara
authors.forename: S
authors.initials: S
authors.lastname: Uzan
authors.forename: R
authors.initials: R
authors.lastname: Rouzier
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy / Q000473:pathology*; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors